The ACTIVE trial tested the hypothesis that longer dialysis would be better for quality of life. Sadly, this did not turn out to be the case. Is the end of longer being better? Join us as we dissect the study at the next NephJC.
Background, news
in this edition: Atacicept in IgAN; Albuminuria as a surrogate outcome, Renal Remission and additional CONFIDENCE analysis
Background
This week, we will discuss the 2025 KDIGO IgAN guidelines. which the shift from supportive care to structured, evidence-based therapy
Background
This week, we will discuss an old dilemma in nephrology. To restrict or supplement the proteins? Premise: advanced CKD and dialysis.
Background, summary
This week, we will discuss the use of creating chimeras to induce immune tolerance and its potential to decrease or eliminate the need for immunosuppression in kidney transplant recipients.
